Across the Atlantic, the main stock market indices completed the session of Tuesday in sharp rise, inspired by inflation in July, observes John Plassard, partner of the Cité Gestion in charge of the investment strategy. The Secretary of State for the Treasury, Scott Bessent, has in the process suggested that the Fed drops its 50 basis rates in September.
The report on the July IPC, however, draws up a nuanced table, with annual inflation which remains stable at 2.7% compared to June and lower than the consensus of 2.8%. But the underlying increased upset, progressing at 3.1% in annual sliding, its highest level since February. “If yesterday the inflation data in the United States was mixed, but the market reaction was not,” said Ipek Ozkardeskaya, analyst of Swissquote Bank.
Among the few macroeconomic data of the day, inflation in Germany remained stable in July, at the target set by the European Central Bank (ECB), according to final figures. Investors will still look into inflation in Spain. And after having digested the few results of companies of the day, including those of the specialist in Straumann dental implants, they will also examine statistics on American real estate.
On the side of the Swiss Stock Exchange, the SMI confirmed the good provisions of investors, the SMI starting the session up 0.23% and barely expanding its winnings at 0.25% in the very first exchanges, to point to 11,915.65 points around 9:20 am. The SLI increased by 0.18% to 1987.26 points, while the enlarged SPI indicator took 0.41% at 16,683.34 points.
Among the 31 constitutive values of the Swiss Leader Index, only seven lost ground, while 23 won, Sig Group doing for its Surlace.
At the bottom of the ranking, Straumann (-2.6%) inherited the red lantern, behind the personnel placement giant Adecco (-0.7%) and the manufacturer of hearing aids Sonova (-0.7%). The Basel manufacturer of dental implants has seen its net profit and its operational profitability drops to the first half of 2025, due to the persistent vigor of the franc. However, the company confirmed its forecasts for 2025.
At the other end of the classification, Amrize (+2.4%) arose in the lead, in front of the manufacturer of elevators and mechanical staircases Schindler (+1.1%) and Richemont (+0.8%), even if Kepler Cheuvreux lowered the lens of the Luxury Geneva giant at 165 francs, against 185 francs previously, the title, however, the title, the title, however,
The three heavyweights on the side, Roche, Novartis and Nestlé found themselves in the bulk of the peloton, displaying respective gains of 0.5, 0.6 and 0.3%.
On the extended market, Santhera jumped 5.1%. The Rhenish laboratory has concluded an exclusive promotion and distribution agreement for its treatment against the myopathy of Duchenne Agamree in Türkiye with its local counterpart Gen ilaç. (Awp)
